Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY R SMITH

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1275502049
CMS profile
148468
Location
SAINT PETERS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$65,207.08

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $33,076.82 31
Biohaven Pharmaceuticals, Inc. $16,376.09 28
Amgen Inc. $7,700.81 8
AbbVie Inc. $4,246.88 5
Teva Pharmaceuticals USA, Inc. $2,020.00 1
Allergan, Inc. $1,750.00 1
Lundbeck LLC $36.48 1

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY R SMITH

NPI 1275502049 · CMS profile ID 148468

Allopathic & Osteopathic Physicians / Internal Medicine

SAINT PETERS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY R SMITH, NPI 1275502049, CMS profile ID 148468. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TIMOTHY R SMITH, NPI 1275502049, CMS profile ID 148468. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TIMOTHY R SMITH, NPI 1275502049, CMS profile ID 148468, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275502049?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $65,207.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $2,700.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818706941 CMS
Biohaven Pharmaceuticals, Inc. $425.0003/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629385 CMS
Lilly USA, LLC $1,200.0003/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818816899 CMS
Lilly USA, LLC $2,700.0003/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818707943 CMS
Lilly USA, LLC $1,200.0003/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818707947 CMS
Lilly USA, LLC $1,200.0003/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818814163 CMS
Biohaven Pharmaceuticals, Inc. $425.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629383 CMS
Lilly USA, LLC $41.5003/09/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818706943 CMS
Biohaven Pharmaceuticals, Inc. $1,275.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629381 CMS
Biohaven Pharmaceuticals, Inc. $425.0003/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629379 CMS
Lilly USA, LLC $1,200.0003/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818814161 CMS
Lilly USA, LLC $1,200.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818765787 CMS
Biohaven Pharmaceuticals, Inc. $1,500.0002/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629377 CMS
Lilly USA, LLC $600.0002/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818684779 CMS
Lilly USA, LLC $18.8202/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818801445 CMS
Lilly USA, LLC $13.2302/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818761839 CMS
Biohaven Pharmaceuticals, Inc. $425.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629375 CMS
Lilly USA, LLC $600.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818706945 CMS
Lilly USA, LLC $600.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818707945 CMS
Biohaven Pharmaceuticals, Inc. $425.0002/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629373 CMS
Biohaven Pharmaceuticals, Inc. $1,700.0002/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629369 CMS
Biohaven Pharmaceuticals, Inc. $19.3002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629371 CMS
Biohaven Pharmaceuticals, Inc. $425.0002/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629367 CMS
Biohaven Pharmaceuticals, Inc. $1,275.0001/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852629365 CMS
Allergan, Inc. $1,750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792949949 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $143,464.37 288
PY2020 $125,643.08 131
PY2021 $65,207.08 75
PY2022 $36,929.23 68
PY2023 $27,116.70 91
PY2024 $28,367.29 41
PY2025 $1,036.22 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,600.00 3
PY2025 Principal investigator $4,487,276.50 296
PY2024 Recipient $113,132.20 11
PY2024 Principal investigator $4,680,361.26 186
PY2023 Recipient $109,639.43 22
PY2023 Principal investigator $4,150,716.29 270
PY2022 Recipient $10,267.00 8
PY2022 Principal investigator $2,852,345.29 506
PY2021 Recipient $200.00 1
PY2021 Principal investigator $2,481,488.34 138
PY2020 Recipient $10,145.59 7
PY2020 Principal investigator $1,518,161.92 141
PY2019 Recipient $4,893.84 4
PY2019 Principal investigator $786,813.56 137

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

299 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 12/17/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762721
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 12/17/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762723
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 12/17/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762725
Principal investigator 1 Eli Lilly and Company $43,177.60 12/16/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL (ATTAIN-OA PAIN) ; J2A-MC-GZT1 ; J2A-MC-GZT2 No dispute reported 06/30/2026 1187890342
Principal investigator 1 Merz Pharmaceuticals, LLC $13,700.00 12/10/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647518
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 12/10/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647520
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 12/10/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647522
Principal investigator 1 Merz Pharmaceuticals, LLC $13,700.00 12/10/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647524
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,820.00 12/03/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813409
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762669
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762671
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762673
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 11/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762675
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762677
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187893354
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,076.00 11/13/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813473
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,171.00 11/05/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813407
Principal investigator 1 PFIZER INC. $42,945.54 11/04/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228724472
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762709
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762711
Principal investigator 1 Amgen Inc. $7,879.58 10/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648842
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762713
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762715
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762717
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762719
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220762727
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220762729
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $525.00 10/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813467
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 10/23/2025 Non-covered Recipient Entity
STUDY METRIX RESEARCH LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309452
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,660.00 10/21/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813463
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 10/21/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813465
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 10/17/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813405
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,126.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813399
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,160.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813401
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813403
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $115.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813445
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813447
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,292.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813449
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813451
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $345.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813453
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813455
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813457
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813459
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 10/15/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813461
Recipient PFIZER INC. $940.00 10/09/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726963
Recipient PFIZER INC. $330.00 10/09/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727861
Recipient PFIZER INC. $330.00 10/09/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727863
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $390.00 10/03/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,429.76 10/03/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813471
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762667
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762705
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762707
Principal investigator 1 Eli Lilly and Company $111.45 09/30/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187893352
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,075.00 09/26/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813395
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $75.00 09/26/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813397
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 09/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762661
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762663
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 09/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762665
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762703
Principal investigator 1 Amgen Inc. $24,800.00 09/23/2025 Non-covered Recipient Entity
EXPERT RESEARCH SOLUTIONS LLC STUDYMETRIX CONSULTING
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246641341
Principal investigator 1 PFIZER INC. $5,210.80 09/09/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228758770
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 09/08/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522094
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,113.00 09/08/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522096
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 09/08/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522098
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,334.00 09/03/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813393
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762641
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762643
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762697
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 08/26/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762659
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 08/26/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762699
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 08/26/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762701
Principal investigator 1 PFIZER INC. $30,699.20 08/26/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228785218
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,520.00 08/21/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813443
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813383
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813385
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813391
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,118.35 08/19/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309006
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/07/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813387
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/07/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813389
Principal investigator 1 PFIZER INC. $42,453.60 08/05/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228767371
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762529
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762695
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,352.00 08/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $492.00 07/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522086
Principal investigator 1 Alnylam Pharmaceuticals Inc. $756.44 07/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522088
Principal investigator 1 Alnylam Pharmaceuticals Inc. $812.00 07/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522090
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762657
Principal investigator 1 Eli Lilly and Company $11,865.00 07/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187889616
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 07/25/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522080
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 07/25/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522082
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/25/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522084
Principal investigator 1 PFIZER INC. $1,570.10 07/18/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228782437
Principal investigator 1 PFIZER INC. $25,709.00 07/15/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764301
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,180.00 07/09/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,391.55 07/02/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522092
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762645
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762647
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762649
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762651
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762653
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762655
Principal investigator 1 Boehringer Ingelheim International GmbH $61.58 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762679
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762681
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762683
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762687
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762689
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762691
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762693
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,619.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813377
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 07/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813437
Principal investigator 1 PFIZER INC. $27,484.80 06/26/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228792392
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,052.00 06/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813431
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762637
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 06/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762639
Principal investigator 1 Amgen Inc. $16,006.40 06/23/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648854
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,000.00 06/20/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522008
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 06/20/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522010
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,085.00 06/12/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 06/09/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215522004
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 06/09/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813423
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.00 06/09/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813425
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 06/05/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813373
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 06/05/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813429
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 06/04/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813371
Principal investigator 1 Eli Lilly and Company $222,868.28 06/02/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187890312
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762507
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762509
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762511
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762513
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762611
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762613
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762615
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762617
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762619
Principal investigator 1 PFIZER INC. $14,149.10 05/31/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764866
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762523
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762525
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762527
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762629
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762631
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762633
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 05/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762635
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $136.00 05/26/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813421
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $136.00 05/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813419
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,209.00 05/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813433
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $75.00 05/19/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813435
Principal investigator 1 PFIZER INC. $35,975.10 05/14/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228773149
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $80.00 05/12/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813379
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $80.00 05/12/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813441
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,386.00 05/09/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813417
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $175.16 05/06/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813369
Principal investigator 1 PFIZER INC. $23,524.90 05/06/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228772647
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,225.00 05/05/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813367
Principal investigator 1 PFIZER INC. $69,871.90 05/03/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228772911
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762499
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762501
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762503
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762505
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762601
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762603
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762605
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762607
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762609
Principal investigator 1 Amgen Inc. $23,769.00 04/24/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1246648838
Principal investigator 1 Eli Lilly and Company $8,613.01 04/24/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187890664
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762515
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762517
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762519
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762521
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762621
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762623
Principal investigator 1 Boehringer Ingelheim International GmbH $26.10 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762625
Principal investigator 1 Boehringer Ingelheim International GmbH $33.12 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762627
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $376.80 04/23/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813365
Principal investigator 1 Eli Lilly and Company $2,019.36 04/23/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187890340
Principal investigator 1 PFIZER INC. $44,349.90 04/18/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228795997
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,386.34 04/17/2025 Non-covered Recipient Entity
STUDY METRIX RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,360.00 04/11/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813363
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,718.00 04/11/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813415
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,180.00 04/10/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813413
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762491
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762493
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762495
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762497
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762591
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762593
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762595
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762597
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762599
Principal investigator 1 Novo Nordisk AS $2,402.88 03/28/2025 Non-covered Recipient Entity
ROVIA STUDYMETRIX RESEARCH
NN9535-4984 No dispute reported 06/30/2026 1213816981
Principal investigator 1 Boehringer Ingelheim International GmbH $331.65 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762487
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762489
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762577
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762579
Principal investigator 1 Boehringer Ingelheim International GmbH $331.65 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762581
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762583
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762585
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 03/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762587
Principal investigator 1 Eli Lilly and Company $857.06 03/25/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187890172
Principal investigator 1 Eli Lilly and Company $3,897.52 03/25/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187891670
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,026.00 03/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813427
Principal investigator 1 PFIZER INC. $28,113.40 03/22/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228787134
Principal investigator 1 Eli Lilly and Company $429.14 03/21/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187893346
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,085.00 03/13/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813361
Principal investigator 1 Eli Lilly and Company $8,424.00 03/10/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1187890718
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762467
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762469
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762471
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762473
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762553
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762555
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762557
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762559
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762561
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762563
Principal investigator 1 ABBVIE INC. $575.00 02/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202454511
Principal investigator 1 ABBVIE INC. $3,706.50 02/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202454521
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762481
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762483
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762485
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762569
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762571
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762573
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 02/25/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762575
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,280.00 02/20/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813359
Principal investigator 1 Eli Lilly and Company $1,772.66 02/14/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187890666
Principal investigator 1 PFIZER INC. $12,761.00 02/14/2025 Non-covered Recipient Entity
StudyMetrix Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228761923
Principal investigator 1 Eli Lilly and Company $51,683.00 02/04/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187892572
Principal investigator 1 Eli Lilly and Company $77,268.54 02/03/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890716
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762453
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762455
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762457
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762459
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762461
Principal investigator 1 Boehringer Ingelheim International GmbH $64.50 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762463
Principal investigator 1 Boehringer Ingelheim International GmbH $21.50 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762465
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762539
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762541
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762543
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762545
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762547
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762549
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762551
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,763.00 02/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813357
Principal investigator 1 Eli Lilly and Company $645.85 01/31/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187889614
Principal investigator 1 Eli Lilly and Company $872.76 01/31/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187889714
Principal investigator 1 Eli Lilly and Company $728.36 01/31/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187889716
Principal investigator 1 Eli Lilly and Company $445.84 01/31/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187892936
Principal investigator 1 Eli Lilly and Company $732.11 01/31/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187892938
Principal investigator 1 Eli Lilly and Company $6,756.06 01/31/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187892940
Principal investigator 1 Amgen Inc. $30,717.81 01/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1246648850
Principal investigator 1 Eli Lilly and Company $185,573.98 01/28/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187891076
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,608.00 01/28/2025 Non-covered Recipient Entity
STUDY METRIX RESEARCH LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190307951
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762475
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762477
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 01/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762479
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762565
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762567
Principal investigator 1 Eli Lilly and Company $494.10 01/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187889712
Principal investigator 1 Eli Lilly and Company $119,405.00 01/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187890720
Principal investigator 1 Eli Lilly and Company $2,806.01 01/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187891672
Principal investigator 1 Eli Lilly and Company $333,575.00 01/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187892574
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,124.58 01/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309002
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $764.99 01/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813349
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $589.43 01/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813351
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 01/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813353
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $785.28 01/24/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813355
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 01/22/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220813347
Principal investigator 1 Eli Lilly and Company $37,866.08 01/21/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187889710
Principal investigator 1 Eli Lilly and Company $395,101.00 01/21/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187890166
Principal investigator 1 Eli Lilly and Company $116,701.00 01/21/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187890714
Principal investigator 1 Eli Lilly and Company $167,761.91 01/21/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187891316
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,720.00 01/17/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220813411
Principal investigator 1 Eli Lilly and Company $55.20 01/16/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187890164
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,088.80 01/15/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309004
Principal investigator 1 Eli Lilly and Company $71,261.32 01/13/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890086
Principal investigator 1 Eli Lilly and Company $3,534.12 01/09/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890090
Principal investigator 1 Eli Lilly and Company $10,997.85 01/09/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187890310
Principal investigator 1 Eli Lilly and Company $4,352.69 01/09/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187893348
Principal investigator 1 Eli Lilly and Company $130,185.00 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187890088
Principal investigator 1 Eli Lilly and Company $219,033.00 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) No dispute reported 06/30/2026 1187890168
Principal investigator 1 Eli Lilly and Company $125,559.00 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187890170
Principal investigator 1 Eli Lilly and Company $206,925.87 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187890308
Principal investigator 1 Eli Lilly and Company $212,086.00 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187890336
Principal investigator 1 Eli Lilly and Company $153,019.77 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187891318
Principal investigator 1 Eli Lilly and Company $441,539.56 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187892576
Principal investigator 1 Eli Lilly and Company $54,145.16 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187892578
Principal investigator 1 Eli Lilly and Company $178,442.00 01/07/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187892580
Principal investigator 1 Eli Lilly and Company $1,504.21 01/03/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187889708
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762445
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762447
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762449
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220762451
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762531
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762533
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762535
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762537
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Study Metrix Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220762589